Dostarlimab (NCT05239546)

Name: Dostarlimab trial for Colon Cancer (NCT05239546)
Uploaded: 2026-11-01T00:03:54.069Z
Duration: 1 min 25 s
Description: Dostarlimab trial for Colon Cancer (NCT05239546). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05239546.

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers: a one-minute explainerNCT052395461 min

Dostarlimab trial for Colon Cancer (NCT05239546). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with operable stage-two or stage-three colon cancer that is mismatch-repair-deficient. T4b tumors, distant spread, or urgent obstruction, perforation, or bleeding exclude entry. Patients must accept avoiding surgery if study criteria are met.

The idea: dostarlimab blocks the PD1 immune brake. Infusions start every three weeks for six cycles, then every six weeks. Researchers assess blood tumor DNA, symptoms, and distant spread at eighteen weeks. Surgery remains an option for nonresponse.

This phase 2 study plans 25 patients. Saima Sharif leads at Iowa; Iowa City and Madison recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.